A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
NCT ID: NCT06994897
Last Updated: 2025-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
92 participants
INTERVENTIONAL
2025-08-13
2027-12-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is seeking participants who
* are male or female between 18 and 45 years of age (55 for Japanese/Chinese/multiple dose participants)
* are deemed to be healthy
Participants in this study will receive PF-07985631 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.
PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) or as an IV infusion in the arm (given directly into a vein) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo once a month for 3 months.
The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective.
Participants who take PF-07985631 or placebo only 1 time will take part in this study for about 4 months. During this time, they will stay at the study clinic for 11 to 14 days and will have 8 more study visits at the study clinic.
Participants who take PF-07985631 or placebo more than once will take part in this study for about 6 months. During this time, they will stay at the study clinic for about 4 days a month 3 times and will have 10 more study visits at the study clinic.
During study clinic stays and study visits, blood samples will be done and safety reviews completed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults
NCT07235150
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
NCT07315360
A Renal Impairment Study for PF-04965842
NCT03660241
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
NCT00596518
Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.
NCT04909853
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: single ascending dose
Dose A (3 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 2: single ascending dose
Dose B (3 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 3: single ascending dose
Dose C (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 4: single ascending dose
Dose D (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 5: single ascending dose
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 6: single ascending dose
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 7: single ascending dose
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 8: single dose
Optional Japanese Cohort dose to be determined (4 active: 1 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 9: single dose
Optional Chinese Cohort dose to be determined (4 active: 1 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 10: multiple dose
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 11
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 12
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Cohort 13
Optional Cohort with dose to be determined (6 active: 2 placebo)
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-07985631
Experimental Pfizer compound which will be SC or IV
Placebo
Placebo which will be SC or IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Japanese/Chinese and multiple dose cohorts only: Adult participants 18 to 55 years of age who are overtly healthy may be eligible at the discretion of PI.
3. Japanese/Chinese cohorts only: Participants must have 4 biological Japanese/Chinese grandparents who were born in Japan/China.
Exclusion:
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
2. Participants with a history of allergic or anaphylactic reaction with any investigative biologic agents.
3. History of infections requiring treatment within 28 days prior to Day 1 or any active infection at Day 1.
4. Active or latent infection with tuberculosis.
5. History of recurrent urinary tract infections AND/OR sinopulmonary infections AND/OR gastrointestinal infections requiring antibiotic treatment.
6. Known fever within the 7 days prior to dosing.
7. Active gastrointestinal (GI) tract ulcerations or GI bleeding.
8. Vaccination within 6 weeks prior to Day 1 dosing or planned vaccination during the study.
9. Positive urine drug test.
10. Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic).
11. Estimated glomerular filtration rate (eGFR) \<75 mL/min/1.73 m².
12. Chest X-ray showing any active disease in the chest, or pulmonary nodules \>0.5 cm in diameter that have not been previously evaluated, cavitary lesions or evidence of bronchiectasis.
13. Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
14. Positive stool hematest at screening or admission.
15. Participants with ANY of the following abnormalities in clinical laboratory tests at screening:
* Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin (direct and total) ≥1.05 × upper limit of normal
* Immunoglobulin G, Immunoglobulin M, Immunoglobulin A below the lower limit of normal (LLN)
* Total white blood cell (WBC) below the LLN
* Lymphocyte count below the LLN
* Platelet count below the LLN
* Hemoglobin below the LLN
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-519215-33-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
C5661001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.